Salute e Benessere

Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products,the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products...

The 137th Canton Fair Sees a Booming Market for All-Age Toys

"This collection reflects the evolution of toys," said Chen Xiaowei, the company's Deputy Marketing Director. "They're no longer just for children. We're seeing a growing trend among young adults who enjoy the process of building and the beauty of the finished product." According to the company, its sub-brand PANLOS is specifically designed with this audience in mind, targeting consumers between 18 and 35. "This collection reflects the evolution of toys," saidChen…

Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR…

More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECATM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. More than 2,300 attendees — including dignitaries fromItaly,Spain,Germany,France, andCanada— visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was...

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 2 May 2025 at 15.15 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 1...

Implantica presents the first quarter 2025 on May 9 at 15:00 CEST

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica...

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1…

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, N.J., May02, 2025(GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 for patients with wet Age-related Macular Degeneration (wet AMD). This multi-center, open-label,...

Orion Corporation: Managers' transactions – Karen Lykke Sørensen

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Karen Lykke Sørensen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the...

Orion Corporation: Managers' transactions – Henrik Stenqvist

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Orion Corporation: Managers' transactions – Ari Lehtoranta

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Orion Corporation: Managers' transactions – Veli-Matti Mattila

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Orion Corporation: Managers' transactions – Hilpi Rautelin

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Orion Corporation: Managers' transactions – Eija Ronkainen

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Orion Corporation: Managers' transactions – Maziar Mike Doustdar

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Maziar Mike Doustdar Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the...

Orion Corporation: Managers' transactions – Kari Jussi Aho

ORION CORPORATIONMANAGERS' TRANSACTIONS2 MAY 2025 at 11.45 EEST Orion Corporation: Managers' transactions – Kari Jussi Aho Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

Aktiia secures $42 million in Series B funding round and rebrands to Hilo

The latest investment builds on a period of significant momentum for the company during which it has achieved several major milestones, including securing CE marking for its innovative mobile phone camera blood pressure monitoring technology, securing regulatory approvals in Canada, Australia and Saudi Arabia, achieving 76% compounded annual revenue growth, and completing a pivotal clinical trial ahead of its U.S. FDA application submission. This Series B funding will fuel continued product…

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL…

Glasgow, Scotland – 2 May 2025.EnteroBiotix Limited ('EnteroBiotix'), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, the Company's next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam,...

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for…

COPENHAGEN, Denmark, May 2, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA ®(recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.The vaccine was approved following MHRA review under the international recognition procedure, which is a targeted...

301,521 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 301,521 A shares have been converted into 301,521 B shares. The conversion has been entered into the Trade Register on 2 May 2025.The total number of shares in Orion Corporation is 141,134,278...

Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2024, will be held on Wednesday, May 28, 2025, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland. Jean-Paul Clozel, Chairman of the Board of Idorsia, commented:“The team at Idorsia continues to go the extra mile to...

HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion

With the increasing demand for routine clinical testing of Metabolic Dysfunction-Associated Steatohepatitis (MASH), particularly in liver biopsy assessment, this investment is focused on 1) expanding HistoIndex-partnered laboratories and operations within the US; and 2) developing next-generation AI-powered SHG digital pathology tests for MASH patients. With the increasing demand for routine clinical testing of Metabolic Dysfunction-Associated Steatohepatitis (MASH), particularly in liver...

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food…

Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ®FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025COPENHAGEN, Denmark; May 2, 2024 –Genmab A/S(Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S...

IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment…

BioXcel Therapeutics' IGALMI (dexmedetomidine) Overview BioXcel Therapeutics' IGALMI (dexmedetomidine) Overview IGALMI is the first newly approved acute treatment in over ten years for managing agitation linked to schizophrenia or bipolar disorder. It offers a unique approach to addressing this challenging and often distressing symptom. Agitation frequently occurs in individuals with bipolar I or II disorder or schizophrenia and can be difficult to control. Timely recognition and...

EPIDIOLEX Continues to Lead the Way in Cannabinoid-Based Epilepsy Treatment |…

Jazz Pharmaceuticals' EPIDIOLEX (cannabidiol) Overview Jazz Pharmaceuticals' EPIDIOLEX (cannabidiol) Overview EPIDIOLEX (formerly known as GWP42003-P and marketed as EPIDYOLEX inEurope ) is the first plant-based, prescription cannabis-derived oral medication developed by GW Pharmaceuticals. It represents a new category of antiepileptic drugs with a unique mechanism of action. The active compound, cannabidiol (CBD), is a naturally occurring cannabinoid found in theCannabis sativa L...

Altri Comunicati